NEURO-ONCOLOGY

CENTRAL NERVOUS SYSTEM

Porsolt offers models in all areas of psychopharmacology, epilepsy, sleep-wake, and neurodegenerative disorders. We are uniquely placed to offer a full range of CNS efficacy and safety pharmacology assessments, from basic models and regulatory tests, through the evaluation of abuse and dependence liability and proconvulsant risk using EEG.

NEURO-ONCOLOGY

Porsolt offers to screen and to characterize anti-cancer drugs in predictive in vitro models of brain tumors. We also complement in vivo studies with automated brain tumor histopathology services, to assess in vivo drug efficacy and drug mechanism of action at the subcellular level.

IN VITRO MODELS OF HUMAN BRAIN TUMORS

Several in vitro brain tumor models are available at Porsolt to study the underlying mechanisms of tumor development and to test new anticancer drugs:

> Human neuroblastoma cell line (SH-SY5Y)

 

> Human glioblastoma cell lines (DBTRG-O5MG, U-87 MG)

 

Standard cell differentiation procedures can be implemented to induce the expression of a functionally mature neuronal phenotype, as in the case of SH-SY5Y cells.

HIGH-CONTENT HISTOPATHOLOGY OF BRAIN TUMORS

Iba1 and H&E stainings highlight microglia infiltration and reactive astrogliosis within the tumor region in mouse glioblastoma model.

Porsolt applies high-content analysis methodologies to brain tumor tissue samples to support in vivo studies in neuro-oncology. Paraffin-embedded tumor tissues, either in tissue section or tissue microarray format, are analyzed by automated tissue imaging, to investigate the in vivo effect and mechanism of action of drug candidates at the molecular level:

> Tissue microarrays approach: to analyze simultaneously large series of brain tissue samples

 

> Automated and multiplexed tissue imaging of immunostained tissue sections and tissue microarrays (IHC/IF)

 

> Quantitative histological analysis: multiplexed analysis of tissue structure detection, biomarker expression levels and subcellular distribution.